Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference

Core Insights - The LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET), indicating its growing commercial traction and relevance in the field of endovascular procedures [1][3] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY system being the world's first FDA cleared single-use, remotely operated robotic solution [4] Product Highlights - The LIBERTY Endovascular Robotic System is designed for precision vascular navigation, aiming to reduce radiation exposure and physical strain on clinicians [3] - It is the only FDA cleared, single-use endovascular robotic system, which is expected to drive broader adoption in peripheral endovascular interventions as procedures become more complex [2][3] Market Strategy - The company commenced a limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption [3]